Vaccine for Inducing Immune Responses Against CD47-Expressing Cancers
This technology uses engineered bacteriophages displaying CD47-mimicking peptides to stimulate the immune system to produce antibodies that help the body’s immune cells recognize and destroy cancer cells that would otherwise evade detection.
Background
Cancer immunotherapy has emerged as a transformative field in oncology, aiming to harness the immune system to recognize and eliminate malignant cells. One of the critical challenges in this area is overcoming the mechanisms by which tumors evade immune surveillance. The CD47 protein, often referred to as the “don’t eat me” signal, is a cell surface molecule that interacts with the SIRPα receptor on macrophages to inhibit phagocytosis. Many cancers upregulate CD47 expression to avoid being targeted and destroyed by the immune system. As a result, blocking the CD47-SIRPα interaction has become a promising strategy for enhancing the immune-mediated clearance of cancer cells, driving the development of targeted therapies in both human and veterinary medicine.
Current approaches to inhibiting CD47, particularly the use of monoclonal antibodies, have shown therapeutic potential but are hampered by significant limitations. Monoclonal antibodies are expensive to manufacture, require repeated administrations, and often necessitate cold chain logistics, making them less accessible in resource-limited settings. Additionally, passive immunotherapies may lead to immune-related adverse effects and do not always result in durable immune responses. While active immunization strategies, such as vaccines, could potentially offer longer-lasting and more cost-effective protection, existing vaccine platforms have struggled to elicit strong and specific antibody responses against CD47 due to challenges in antigen design and presentation. These shortcomings underscore the need for innovative solutions that can reliably stimulate endogenous anti-CD47 immunity in a safe, scalable, and affordable manner.
Technology
This technology leverages recombinant filamentous bacteriophages, particularly from the Ff class, as platforms to display engineered peptide sequences that mimic key epitopes of the CD47 cell surface protein. By utilizing phage display libraries, researchers identify and select peptides that bind specifically to anti-CD47 monoclonal antibodies, ensuring these mimics closely resemble the natural CD47 epitopes involved in immune evasion by cancer cells. These peptides are then genetically fused to phage coat proteins or chemically conjugated using cross-linking agents such as EDC or sulfo-SMCC, with various molecular linkers optimizing their spatial orientation and immunogenicity. The resulting phage-peptide constructs are formulated into immunogenic compositions, which, when administered, stimulate the host’s immune system to generate endogenous anti-CD47 antibodies. This immune response blocks the interaction between CD47 and SIRPα on macrophages, thereby disrupting the “don’t eat me” signal that cancer cells use to avoid immune destruction and promoting their phagocytosis.
What differentiates this technology is its innovative use of phage display as both a discovery and delivery platform for peptide-based cancer immunotherapy. Unlike traditional monoclonal antibody treatments, which are costly and require repeated administration, this approach enables active immunization, prompting the body to produce its own anti-CD47 antibodies for longer-lasting and potentially more affordable protection. The dense, repetitive display of peptides on the phage surface enhances immunogenicity by mimicking pathogen-associated molecular patterns, often eliminating the need for additional adjuvants. Furthermore, filamentous phages are safe, non-pathogenic, and stable at room temperature, facilitating low-cost production and distribution without cold chain requirements. The platform’s versatility allows for rapid adaptation to various cancer targets and applications in both human and veterinary medicine, making it a broadly applicable and scalable solution in oncology.
Benefits
- Cost-effective production and scalability compared to monoclonal antibody therapies
- Induces endogenous anti-CD47 antibody production for durable immune response
- Blocks CD47-SIRPα interaction, promoting macrophage-mediated phagocytosis of cancer cells
- Safe and non-pathogenic platform using filamentous bacteriophages
- Versatile and rapid identification of immunogenic peptide mimics through phage display
- Stable vaccine formulations that do not require cold chain logistics
- Applicable to both human and veterinary oncology, including canine lymphoma
Applications
- Cancer immunotherapy vaccine development
- Veterinary oncology vaccine products
- Phage display peptide screening
- Personalized cancer vaccine design
Additional info
These recombinant Ff class filamentous bacteriophages display exogenous peptide mimics of CD47 epitopes via genetic fusion or chemical conjugation. When administered, these constructs elicit endogenous antibodies that disrupt the CD47-SIRPα inhibitory pathway. This blockade prevents cancer cells from evading immune surveillance, thereby enhancing macrophage-mediated phagocytosis. The platform utilizes specific sequences like SEQ ID NOs: 1–43 and molecular linkers to optimize immunogenicity for oncology applications.